Anivovetmab Biosimilar - Research Grade

Human

Parvovirus major capsid protein VP2 [Canine parvovirus]

>1mg/ml

IgG2 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

The canine parvovirus major capsid protein VP2 forms the viral capsid and mediates host-cell binding, making it a key antigen in veterinary virology research. This anti-VP2 recombinant monoclonal antibody is supplied as an unconjugated, non-therapeutic analog of anivovetmab for research use only. Produced to in vivo manufacturing standards with low endotoxin, it is manufactured in scalable milligram (mg) to gram (g) quantities to serve bulk and high-throughput laboratories. The reagent is well suited to viral-binding and neutralization assays, in vitro functional screening, and in vivo infection models, delivering dependable, reproducible performance.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Anivovetmab (anti-Parvovirus major capsid protein VP2 [Canine parvovirus]) Biosimilar

Q: Is the Anivovetmab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Anivovetmab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Anivovetmab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Anivovetmab that binds Parvovirus major capsid protein VP2 [Canine parvovirus].